Literature DB >> 22226188

Placement of a retrievable inferior vena cava filter for deep venous thrombosis in term pregnancy.

Yang Liu1, Yan Sun, Shiyi Zhang, Xing Jin.   

Abstract

OBJECTIVE: Venous thromboembolism is a significant cause of morbidity and death in pregnant women. Retrievable vena cava filters were placed right before labor as prophylaxis for peripartum pulmonary embolism. We reviewed the experience of caval filter placement and retrieval in term pregnancy in this study.
METHODS: We reviewed 15 patients with deep venous thrombosis (DVT) of the lower extremity who underwent OptEase (Cordis Corp, New Brunswick, NJ) retrievable vena cava filter placement. DVT was diagnosed by clinical symptoms and Doppler ultrasound imaging. Subcutaneous low-molecular-weight heparin was eased 12 hours before cesarean delivery and restarted 12 hours after delivery. The caval filters were placed suprarenally from the jugular approach and retrieved from the femoral approach.
RESULTS: The filters were successfully placed in all patients on the day of cesarean delivery. No placement-related complications occurred. The caval filter was left in situ as a permanent device in one patient because the captured thrombus within the filter was not eliminated after the thrombolytic therapy. Filters in other 14 patients were retrieved successfully, without difficulty, including in one patient after complete lysis of captured thrombus by the thrombolytic therapy. Oral warfarin therapy was recommended for at least 3 months after hospital discharge, and for at least 6 months in the patient with a caval filter left in situ. All patients were examined by Doppler ultrasound imaging during the follow-up. None presented with symptomatic pulmonary embolism or filter-related complications.
CONCLUSIONS: OptEase retrievable vena cava filter placement and retrieval in term pregnant patients with extensive DVT of the lower extremities is safe, effective, and feasible. The results in our study may justify prophylactic filter placement use right before labor.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226188     DOI: 10.1016/j.jvs.2011.10.107

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

Review 1.  The use of retrievable inferior vena cava filters in pregnancy: Another successful case report, but are we actually making a difference?

Authors:  Lodewyk E Du Plessis; Ben W Mol; John M Svigos
Journal:  Obstet Med       Date:  2016-05-12

Review 2.  Pulmonary embolism in pregnancy.

Authors:  E Conti; L Zezza; E Ralli; C Comito; L Sada; J Passerini; D Caserta; S Rubattu; C Autore; M Moscarini; M Volpe
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

Review 3.  Deep vein thrombosis: current status and nanotechnology advances.

Authors:  Aniket S Wadajkar; Sonia Santimano; Maham Rahimi; Baohong Yuan; Subhash Banerjee; Kytai T Nguyen
Journal:  Biotechnol Adv       Date:  2012-08-23       Impact factor: 14.227

4.  Management of venous thromboembolism secondary to ovarian hyperstimulation syndrome: A case report documenting the first use of a superior vena caval filter for upper limb venous thromboembolism in pregnancy, and the difficulties and complications relating to anticoagulation in antenatal and peri-partum periods.

Authors:  Nicola Mitchell-Jones; Michael McEwan; Mark Johnson
Journal:  Obstet Med       Date:  2016-04-29

5.  Peripartum Primary Prophylaxis Inferior Vena Cava Filter Placement in a Patient with Stage IV B-Cell Lymphoma Presenting with a Pathologic Femur Fracture.

Authors:  David M Sherer; Mudar Dalloul; Henry James Behar; Ghadir Salame; Roy Holland; Harry Zinn; Ovadia Abulafia
Journal:  AJP Rep       Date:  2015-05-15

6.  Thrombolytic Therapy and Aspiration of Clots were Effective in the Removal of a Transient Inferior Vena Cava (IVC) Filter that Captured a Large Thrombus.

Authors:  Norihito Takahashi; Kikuo Isoda; Masaru Hiki; Shinichiro Fujimoto; Hiroyuki Daida
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.